GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has entered into an agreement to divest full commercial rights to Wellbutrin XL® in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation (NYSE, TSX: BVF), for $510 million (£340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany is starting Phase III with an innovative patch for female contraception that combines low dosed ethinylestradiol and gestodene. Approximately 3300 women will be enrolled into two global studies to evaluate the contraceptive reliability of the patch starting in May 2009.
Pfizer And Wisconsin Alumni Research Foundation (WARF) Sign License Agreement
- Details
- Category: Pfizer
Pfizer, Inc (NYSE: PFE), the world's premier biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.
GlaxoSmithKline update: influenza A (H1N1)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain. The company has developed a number of potential interventions which it believes may be of value in efforts to reduce the impact and spread of this new influenza virus.
Outcome of new Mirapexin®/Sifrol® (pramipexole) study
- Details
- Category: Boehringer Ingelheim
Results from an international, placebo-controlled trial,(1) presented for the first time at the American Academy of Neurology (AAN) Annual Meeting in Seattle, U.S.A. demonstrate that Mirapexin® / Sifrol® (pramipexole) also improves depressive symptoms, a common, disabling non-motor symptom of Parkinson's disease (PD), in addition to its established efficacy in treating the motor symptoms of PD.
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors
- Details
- Category: Bayer
Bayer HealthCare AG, Germany has entered into a global agreement with Ardea Biosciences, Inc., San Diego California, USA (Nasdaq: RDEA) focused on the development of small molecule mitogen-activated ERK kinase (MEK) inhibitors for the treatment of solid tumors. These kinases are believed to play an important role in cancer cell proliferation, apoptosis and metastasis, as well as inflammation.
Pfizer Reports First-Quarter 2009 Results
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) has reported financial results for first-quarter 2009. Revenues were $10.9 billion, a decrease of 8% compared with the year-ago quarter. Foreign exchange unfavorably impacted revenues by approximately $640 million or 5%. For first-quarter 2009, U.S. revenues were $5.0 billion, a decrease of 10% compared with the year-ago quarter.
More Pharma News ...
- Q1/2009: Merck Revenues Remain Stable at € 1.9 Billion
- Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
- Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Base
- Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
- Pfizer and Medicines for Malaria Venture Advancing International Research Efforts
- Roche strongly outperforms market in first quarter
- OTC weight loss aid is available in pharmacies across Europe